Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Instantly Dissolving Claritin (Loratadine) RediTabs Now Available in Japan KENILWORTH, NJ -- November 24, 2004 -- Schering-Plough Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the company's subsidiary in Japan, has introduced Claritin® (loratadine) RediTabs®, 10mg Tablet, an instantly dissolving nonsedating antihistamine tablet. RediTabs is available by prescription in Japan for the treatment of allergic rhinitis (AR), chronic idiopathic urticaria (CIU), or hives of unknown cause, and itching associated with skin diseases in adults and children 15 years of age and above. RediTabs, a long-lasting selective H1 receptor antagonist taken once-daily, is the first and only allergy product in Japan designed to orally disintegrate. "The tablet dissolves instantly on the tongue without water, offering patients a convenient way to get allergy relief," said, Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough. " RediTabs now joins the original formulation to provide physicians with more options to help patients properly manage allergy symptoms." A recently conducted survey of 800 allergy sufferers in Japan found more than 60 percent of patients prefer to take RediTabs. Allergic rhinitis, commonly referred to as "hay fever," is estimated to affect 15 million people in Japan. The market for prescription antihistamines in Japan is estimated to exceed $1 billion. Urticaria, a reaction to a variety of substances, including food, drugs and topical agents, and characterized by an eruption of itchy, swollen lesions on the skin, affects an estimated 15 to 25 percent of people at least once in their lives. Approximately 25 percent of urticaria patients develop CIU, which is defined as a case that lasts for a period of at least six weeks and has no identifiable cause. More than 40 percent of prescription antihistamine use in Japan can be attributed to CIU and itching associated with skin diseases such as eczema. was approved by Japan's Ministry of Health, Labor and Welfare (MHLW) in September 2002. The treatment's proven safety and efficacy, without the concern of sedation, has helped make a popularly prescribed antihistamine in Japan. SOURCE: Schering-Plough Corporation E-mail this page to a friend or colleague! To print, use this version